Conclusion

Philip G. Janicak; Stephen R. Marder; Rajiv Tandon; Morris Goldman

doi:10.1007/978-1-4939-0656-7_15

Conclusion

Philip G. Janicak^*, Stephen R. Marder, Rajiv Tandon, Morris Goldman

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Several recent initiatives in the diagnosis and treatment of schizophrenia continue to offer hope for patients suffering from this often devastating illness. These include a reconceptualization of how schizophrenia is diagnosed with a gradual shift from clinical symptom criteria to measurement-based approaches and the use of biological markers. Another major focus is early identification of at-risk and first-episode individuals. This allows for more timely monitoring and treatment interventions which may preclude the evolution into more chronic, less treatment responsive stages of the illness. Finally, strategies to moderate the impact of recurrent episodes, improve functionality, and enhance quality of life should help facilitate the achievement of important personal goals as our patients work towards recovery.

Original language	English (US)
Title of host publication	Schizophrenia
Subtitle of host publication	Recent Advances in Diagnosis and Treatment
Publisher	Springer New York
Pages	315-320
Number of pages	6
ISBN (Electronic)	9781493906567
ISBN (Print)	1493906550, 9781493906550
DOIs	https://doi.org/10.1007/978-1-4939-0656-7_15
State	Published - Feb 1 2014

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-4939-0656-7_15

Cite this

@inbook{934765beabee43b59ee41ce368567313,

title = "Conclusion",

abstract = "Several recent initiatives in the diagnosis and treatment of schizophrenia continue to offer hope for patients suffering from this often devastating illness. These include a reconceptualization of how schizophrenia is diagnosed with a gradual shift from clinical symptom criteria to measurement-based approaches and the use of biological markers. Another major focus is early identification of at-risk and first-episode individuals. This allows for more timely monitoring and treatment interventions which may preclude the evolution into more chronic, less treatment responsive stages of the illness. Finally, strategies to moderate the impact of recurrent episodes, improve functionality, and enhance quality of life should help facilitate the achievement of important personal goals as our patients work towards recovery.",

author = "Janicak, {Philip G.} and Marder, {Stephen R.} and Rajiv Tandon and Morris Goldman",

year = "2014",

month = feb,

day = "1",

doi = "10.1007/978-1-4939-0656-7_15",

language = "English (US)",

isbn = "1493906550",

pages = "315--320",

booktitle = "Schizophrenia",

publisher = "Springer New York",

}

TY - CHAP

T1 - Conclusion

AU - Janicak, Philip G.

AU - Marder, Stephen R.

AU - Tandon, Rajiv

AU - Goldman, Morris

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Several recent initiatives in the diagnosis and treatment of schizophrenia continue to offer hope for patients suffering from this often devastating illness. These include a reconceptualization of how schizophrenia is diagnosed with a gradual shift from clinical symptom criteria to measurement-based approaches and the use of biological markers. Another major focus is early identification of at-risk and first-episode individuals. This allows for more timely monitoring and treatment interventions which may preclude the evolution into more chronic, less treatment responsive stages of the illness. Finally, strategies to moderate the impact of recurrent episodes, improve functionality, and enhance quality of life should help facilitate the achievement of important personal goals as our patients work towards recovery.

AB - Several recent initiatives in the diagnosis and treatment of schizophrenia continue to offer hope for patients suffering from this often devastating illness. These include a reconceptualization of how schizophrenia is diagnosed with a gradual shift from clinical symptom criteria to measurement-based approaches and the use of biological markers. Another major focus is early identification of at-risk and first-episode individuals. This allows for more timely monitoring and treatment interventions which may preclude the evolution into more chronic, less treatment responsive stages of the illness. Finally, strategies to moderate the impact of recurrent episodes, improve functionality, and enhance quality of life should help facilitate the achievement of important personal goals as our patients work towards recovery.

UR - http://www.scopus.com/inward/record.url?scp=84929848383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929848383&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-0656-7_15

DO - 10.1007/978-1-4939-0656-7_15

M3 - Chapter

AN - SCOPUS:84929848383

SN - 1493906550

SN - 9781493906550

SP - 315

EP - 320

BT - Schizophrenia

PB - Springer New York

ER -

Conclusion

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this